Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

Anne Sophie Kubasch; Freya Schulze; Aristoteles Giagounidis; Katharina S. Götze; Jan Krönke; Katja Sockel; Jan Moritz Middeke; Fatiha Chermat; Silke Gloaguen; Martin Puttrich; Carmen Weigt; Doreen William; Pierre Fenaux; Richard F. Schlenk; Christian Thiede; Sebastian Stasik; Anna Mies; Lionel Adès; Uta Oelschlägel; Uwe Platzbecker

doi:10.1038/s41375-019-0645-z

Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

Anne Sophie Kubasch, Freya Schulze, Aristoteles Giagounidis, Katharina S. Götze, Jan Krönke, Katja Sockel, Jan Moritz Middeke, Fatiha Chermat, Silke Gloaguen, Martin Puttrich, Carmen Weigt, Doreen William, Pierre Fenaux, Richard F. Schlenk, Christian Thiede, Sebastian Stasik, Anna Mies, Lionel Adès, Uta Oelschlägel, Uwe Platzbecker

Department of Internal Medicine III - Hematology and Medical Oncology

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Original language	English
Pages (from-to)	1182-1186
Number of pages	5
Journal	Leukemia
Volume	34
Issue number	4
DOIs	https://doi.org/10.1038/s41375-019-0645-z
State	Published - Apr 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41375-019-0645-z

Cite this

Kubasch, A. S., Schulze, F., Giagounidis, A., Götze, K. S., Krönke, J., Sockel, K., Middeke, J. M., Chermat, F., Gloaguen, S., Puttrich, M., Weigt, C., William, D., Fenaux, P., Schlenk, R. F., Thiede, C., Stasik, S., Mies, A., Adès, L., Oelschlägel, U., & Platzbecker, U. (2020). Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia, 34(4), 1182-1186. https://doi.org/10.1038/s41375-019-0645-z

@article{35ebbf9abcaa4ea38a0fbdbb458821d7,

title = "Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents",

author = "Kubasch, {Anne Sophie} and Freya Schulze and Aristoteles Giagounidis and G{\"o}tze, {Katharina S.} and Jan Kr{\"o}nke and Katja Sockel and Middeke, {Jan Moritz} and Fatiha Chermat and Silke Gloaguen and Martin Puttrich and Carmen Weigt and Doreen William and Pierre Fenaux and Schlenk, {Richard F.} and Christian Thiede and Sebastian Stasik and Anna Mies and Lionel Ad{\`e}s and Uta Oelschl{\"a}gel and Uwe Platzbecker",

note = "Funding Information: Funding The study was sponsored by Janssen Research & Development, LLC.",

year = "2020",

month = apr,

doi = "10.1038/s41375-019-0645-z",

language = "English",

volume = "34",

pages = "1182--1186",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "4",

}

Kubasch, AS, Schulze, F, Giagounidis, A, Götze, KS, Krönke, J, Sockel, K, Middeke, JM, Chermat, F, Gloaguen, S, Puttrich, M, Weigt, C, William, D, Fenaux, P, Schlenk, RF, Thiede, C, Stasik, S, Mies, A, Adès, L, Oelschlägel, U & Platzbecker, U 2020, 'Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents', Leukemia, vol. 34, no. 4, pp. 1182-1186. https://doi.org/10.1038/s41375-019-0645-z

TY - JOUR

T1 - Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

AU - Kubasch, Anne Sophie

AU - Schulze, Freya

AU - Giagounidis, Aristoteles

AU - Götze, Katharina S.

AU - Krönke, Jan

AU - Sockel, Katja

AU - Middeke, Jan Moritz

AU - Chermat, Fatiha

AU - Gloaguen, Silke

AU - Puttrich, Martin

AU - Weigt, Carmen

AU - William, Doreen

AU - Fenaux, Pierre

AU - Schlenk, Richard F.

AU - Thiede, Christian

AU - Stasik, Sebastian

AU - Mies, Anna

AU - Adès, Lionel

AU - Oelschlägel, Uta

AU - Platzbecker, Uwe

N1 - Funding Information: Funding The study was sponsored by Janssen Research & Development, LLC.

PY - 2020/4

Y1 - 2020/4

UR - http://www.scopus.com/inward/record.url?scp=85075940934&partnerID=8YFLogxK

U2 - 10.1038/s41375-019-0645-z

DO - 10.1038/s41375-019-0645-z

M3 - Article

C2 - 31796915

AN - SCOPUS:85075940934

SN - 0887-6924

VL - 34

SP - 1182

EP - 1186

JO - Leukemia

JF - Leukemia

IS - 4

ER -

Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

UN SDGs

Access to Document

Other files and links

Cite this